NASDAQ:COLLCollegium Pharmaceutical Stock Price, Forecast & News

Collegium Pharmaceutical's stock was trading at $17.57 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, COLL shares have decreased by 4.4% and is now trading at $16.79. View which stocks have been most impacted by Coronavirus.

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Collegium Pharmaceutical in the last year. There are currently 2 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Collegium Pharmaceutical.

Collegium Pharmaceutical is scheduled to release its next quarterly earnings announcement on Wednesday, August 5th 2020. View our earnings forecast for Collegium Pharmaceutical.

Collegium Pharmaceutical Inc (NASDAQ:COLL) released its earnings results on Thursday, May, 7th. The specialty pharmaceutical company reported $0.01 earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of $0.66 by $0.65. The specialty pharmaceutical company earned $76.51 million during the quarter, compared to the consensus estimate of $76.64 million. Collegium Pharmaceutical had a negative net margin of 4.21% and a negative return on equity of 12.62%. The firm's revenue for the quarter was up 2.7% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.29) earnings per share. View Collegium Pharmaceutical's earnings history.

Collegium Pharmaceutical issued an update on its FY 2020 After-Hours earnings guidance on Thursday, May, 7th. The company provided EPS guidance of for the period. The company issued revenue guidance of $300-320 million, compared to the consensus revenue estimate of $318.44 million.

8 Wall Street analysts have issued 12 month price targets for Collegium Pharmaceutical's stock. Their forecasts range from $22.00 to $43.00. On average, they anticipate Collegium Pharmaceutical's share price to reach $32.50 in the next twelve months. This suggests a possible upside of 93.6% from the stock's current price. View analysts' price targets for Collegium Pharmaceutical.

Media headlines about COLL stock have trended negative recently, according to InfoTrie Sentiment Analysis. InfoTrie rates the sentiment of news coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Collegium Pharmaceutical earned a media sentiment score of -2.1 on InfoTrie's scale. They also assigned headlines about the specialty pharmaceutical company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the company's share price in the immediate future. View the latest news about Collegium Pharmaceutical.

Collegium Pharmaceutical saw a increase in short interest during the month of June. As of June 30th, there was short interest totaling 5,020,000 shares, an increase of 13.3% from the June 15th total of 4,430,000 shares. Based on an average daily volume of 457,800 shares, the days-to-cover ratio is presently 11.0 days. Approximately 15.8% of the company's shares are short sold. View Collegium Pharmaceutical's Current Options Chain.

Some companies that are related to Collegium Pharmaceutical include Turning Point Therapeutics (TPTX), SAGE Therapeutics (SAGE), IGM Biosciences (IGMS), Uniqure (QURE), Corcept Therapeutics (CORT), Eidos Therapeutics (EIDX), Dicerna Pharmaceuticals (DRNA), Principia Biopharma (PRNB), Xencor (XNCR), Prestige Consumer Healthcare (PBH), Ligand Pharmaceuticals (LGND), Aurinia Pharmaceuticals (AUPH), Zymeworks (ZYME), Myovant Sciences (MYOV) and Akebia Therapeutics (AKBA). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Collegium Pharmaceutical investors own include GALAPAGOS NV/S (GLPG), AbbVie (ABBV), NVIDIA (NVDA), Canopy Growth (CGC), Gilead Sciences (GILD), Inovio Pharmaceuticals (INO), Bausch Health Companies (BHC), Intercept Pharmaceuticals (ICPT), Advanced Micro Devices (AMD) and GW Pharmaceuticals PLC- (GWPH).

(COLL) raised $75 million in an initial public offering on Thursday, May 7th 2015. The company issued 5,800,000 shares at $12.00-$14.00 per share. Jefferies and Piper Jaffray served as the underwriters for the IPO and Wells Fargo Securities and Needham & Company were co-managers.

Collegium Pharmaceutical trades on the NASDAQ under the ticker symbol "COLL."

Collegium Pharmaceutical's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Envestnet Asset Management Inc. (0.03%). Company insiders that own Collegium Pharmaceutical stock include Alison B Fleming, David Hirsch, Joseph Ciaffoni, Michael Thomas Heffernan and Scott Dreyer. View institutional ownership trends for Collegium Pharmaceutical.

COLL stock was purchased by a variety of institutional investors in the last quarter, including Envestnet Asset Management Inc.. View insider buying and selling activity for Collegium Pharmaceutical.

Shares of COLL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of COLL stock can currently be purchased for approximately $16.79.

Collegium Pharmaceutical has a market capitalization of $576.57 million and generates $296.70 million in revenue each year. The specialty pharmaceutical company earns $-22,720,000.00 in net income (profit) each year or ($0.68) on an earnings per share basis. Collegium Pharmaceutical employs 266 workers across the globe.

The official website for Collegium Pharmaceutical is www.collegiumpharma.com.

Collegium Pharmaceutical's mailing address is 100 Technology Center Drive, Stoughton MA, 02072. The specialty pharmaceutical company can be reached via phone at 781-713-3699.